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The Allosteric Hemoglobin Effector ITPP Inhibits
Metastatic Colon Cancer in Mice
Perparim Limani, MD, Michael Linecker, MD, Marcel A. Schneider, MD, Philipp Kron, MD,
Christoph Tschuor, MD, Ekaterina Kachaylo, PhD, Udo Ungethuem, Claude Nicolau, PhD,y
Jean-Marie Lehn, PhD,z Rolf Graf, PhD, Bostjan Humar, PhD, and Pierre-Alain Clavien, MD, PhD
Objective: To test the effects of enhanced intracellular oxygen contents on
the metastatic potential of colon cancer.
Background: Colorectal cancer is the commonest gastrointestinal carcino-
ma. Distant metastases occur in half of patients and are responsible for most
cancer-related deaths. Tumor hypoxia is central to the pathogenesis of
metastases. Myo-Inositoltrispyrophosphate (ITPP), a nontoxic, antihypoxic
compound, has recently shown significant benefits in experimental cancer,
particularly when combined with standard chemotherapy. Whether ITPP
protects from distant metastases in primary colon cancer is unknown.
Methods: ITPP alone or combined with FOLFOX was tested in a mouse
model with cecal implantation of green fluorescent protein-labeled syngeneic
colorectal cancer cells. Tumor development was monitored through longitu-
dinal magnetic resonance imaging-based morphometric analysis and survival.
Established serum markers of tumor spread were measured serially and
circulating tumor cells were detected via fluorescence measurements.
Results: ITPP significantly reduced the occurrence of metastases as well as
other indicators of tumor aggressiveness. Less circulating tumor cells along
with reduction in malignant serummarkers (osteopontin, Cxcl12) were noted.
The ITPP benefits also affected the primary cancer site. Importantly, animals
treated with ITPP had a significant survival benefit compared with respective
controls, while a combination of FOLFOXwith ITPP conferred the maximum
benefits, including dramatic improvements in survival (mean 86 vs 188 d).
Conclusions: Restoring oxygen in metastatic colon cancer through ITPP
inhibits tumor spread and markedly improves animal survival; an effect that is
enhanced through the application of subsequent chemotherapy. These prom-
ising novel findings call for a clinical trial on ITPP in patients with colorectal
cancer, which is under way.
Keywords: colorectal cancer, hypoxia, ITPP, metastases, myo-
inositoltrispyrophosphate, tumor angiogenesis
(Ann Surg 2017;xx:xxx–xxx)
C olorectal cancer (CRC) is the third most common malignantdisease.1,2 About half of patients eventually present with distant
metastases, greatly contributing to the cancer-related death toll.3
Besides improving the treatment of metastases, death rates might be
lowered with better strategies against locally invasive CRC that has
not spread to distant sites yet. Stage III disease currently is being
treated with surgery and adjuvant chemotherapy (folinic acid, fluo-
rouracil, oxaliplatin [FOLFOX] and similar regimens). A significant
proportion of stage III patients however do not seem to benefit from
chemotherapy.4
Over the last decade, novel biological agents with antiangio-
genic activity (eg, bevacizumab) have been added to standard
chemotherapy against metastatic CRC. Despite early successes,5–7
antiangiogenic approaches seem to be less effective than initially
anticipated and do not confer any benefits in stage III CRC.4,8
Rapid tumor growth leads to a paucity of vessels in the core,
causing an insufficient supply with oxygen and nutrients. The
developing hypoxia provokes a tumor response that is driven through
the hypoxia-inducible factors (HIFs) and includes vascular endothe-
lial growth factor (VEGF)-mediated angiogenesis.9 Antiangiogenic
therapy has been designed to starve tumors by pruning vessels.5
However, the lack of vessels may increase hypoxia and thereby foster
the hypoxic response, a recognized promoter of malignant conver-
sion.8 Accordingly, anti-VEGF treatment for CRC metastasis overall
comes with little benefit in terms of survival, and may even worsen
outcomes in other cancers.8,10
Since tumor hypoxia is a key driver of malignancy, targeting
hypoxia directly may be more effective against dissemination than
antiangiogenic approaches.11–13 Myo-inositoltrispyrophosphate
(ITPP) is a synthetic derivative of myoinositol hexakisphosphate,
an allosteric effector of hemoglobin.14 Like the latter, ITPP decreases
the binding affinity of hemoglobin to oxygen, leading to an enhanced
release of oxygen specifically under hypoxic conditions. Addition-
ally, ITPP readily accumulates in erythrocytes, enabling an increased
oxygen release also in vivo.15 Thus, ITPP is able to elevate oxygen
pressure in hypoxic tumors, thereby suppressing the HIFs and the
hypoxic tumor response, including the angiogenic switch.16 Its
favorable toxicity profile animated the assessment of ITPP in several
animal cancer models. Importantly, ITPP treatment improves sur-
vival of cancer-bearing animals, particularly if combined with
cytotoxic agents.16–23 Recently, we observed a prolonged survival
through ITPP in a mouse model of established CRC liver metastasis,
with a marked potentiation of efficacy when combined with FOL-
FOX.16,24 However, whether ITPP can counteract the spread of CRC
to distant sites is unknown. Likewise, whether an antimetastatic
effect would translate into an improved survival has not been
addressed so far.
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Here, we used a syngeneic orthotopic CRC model based on
cecal implantation of CRC cells to determine whether ITPP has the
potential to inhibit metastatic spread leading to a prolonged survival,
and whether a combination with standard chemotherapy might
potentiate resulting benefits.
METHODS
Animals
C57Bl/6 mice (Harlan, Itlingen, Switzerland) aged 10 to
12 weeks were kept on a 12-hour day/night cycle with free access
to food and water. All animal experiments were in accordance with
Swiss federal animal regulations and approved by the cantonal
veterinary office of Zurich.
Cell Culture, Animal Procedures, Treatment, and
Small Animal MRI
Green fluorescent protein (GFP)-labeled MC-38 CRC cells
(C57Bl/6-syngeneic) were cultured under standard conditions.24
Cecal injection of tumor cells was performed as reported.25 ITPP
was synthetized and administered as a solution containing calcium
chloride to balance its chelating effects as described.15,16 The
procedures for FOLFOX treatment16,26 and the small animal mag-
netic resonance imaging protocol have been reported.24 The treat-
ment schedule including experimental groups is depicted in Figure 1.
Histological Examination, Immunohistochemistry,
GFP detection
Hematoxylin and Eosin staining and immunohistochemistry
for KI67 was performed on 3-mm archived sections as reported.16
KI67 positivity was digitally assessed using AnalySISD 5.0 software
(Olympus, Hamburg, Germany). The numbers of circulatory tumor
cells were indirectly determined by measuring serum GFP-fluores-
cence using a Biotek Cytation 3 Reader (Biotek, Luzern,
Switzerland).
Quantitative Real-time Polymerase Chain Reaction
Total RNAwas extracted from50mg tissue usingTrizol reagent
(Invitrogen, Basel, CH, Switzerland). Quantitative real-time PCR was
performed on cDNA (ThermoScript reverse-transcription PCR Sys-
tem, Invitrogen) using an ABI Prism 7500 Sequence Detector System
and predesigned assays (PE Applied Biosystems, Rotkreuz, CH,
Switzerland): Cdh1, Mm01247357_m1; Hif1a, Mm00468869_m1;
Hif2a, Mm01236112_m1; Ocln, Mm00500912_m1; Snai1,
Mm00441533_g1; Src, Mm00436785_m1, Twist1, Mm00442036_
m1; Vegfa, Mm01281449_m1; Vim, Mm01333430_m1. Results rep-
resent mean fold induction (2DCt) SD relative to the normalization
control reagent 18SrRNA.
Enzyme-linked Immunosorbent Assay (ELISA)
ELISAs for VEGF (order number DY493), osteopontin
(MOST00), CXCL12 (MCX120) were from R&D Systems
(Minneapolis, MN); for HMGB1 (ST51011) from IBL International
(Hamburg, D); and for HIF1A/HIF2A (E90798Mu/E93466Mu) from
NewLife BioChemEX (Bethesda, MD). Triplicate measurements
were performed.
Statistical Analysis
GraphPad Prism (GraphPad Software Inc, La Jolla, CA) was
used. Groups were compared with a t test or 1-way analysis of
variance with post-hoc Bonferroni correction where appropriate.
Significances were categorized according to levels (ns nonsignifi-
cant, P< 0.05, P< 0.01, P< 0.001). Mean SD is shown. Six
animals/group were analyzed unless otherwise stated.
RESULTS
ITPP Downregulates HIF Activities in the
Primary Tumor
Hypoxia leads to the activation of the HIFs, chief transmitters
of the hypoxic tumor response. Consistent with previous findings,16
ITPP treatment of mice (Fig. 1) reduced both Hif1a/2a gene expres-
sion and HIF1A/2A protein levels in the primary CRC (Fig. 2A).
Importantly, reductions were seen immediately after treatment but
also 6 weeks later, indicating a lasting ITPP effect. The down-
regulation of nuclear HIF1A/2Awas associated with reduced tumoral
expression of angiogenic Vegfa, a key transcriptional target of the
HIFs (Fig. 2B). Accordingly, circulating VEGF protein was lowered
in sera following ITPP treatment. Therefore, ITPP treatment leads to
a stable inhibition of HIF activities in the primary tumor.
ITPP Slows the Growth and the Malignant
Potential of the Primary Tumor
The inhibition of HIF activities through ITPP should slow
tumor development.16 When assessing the volume of the primary
CRC, ITPP treatment reduced the size both in a short and long term
(Fig. 3A), along with congruent changes in the proliferation marker
KI67 (Fig. 3B).
HIFs are known promoters of the epithelial-to-mesenchymal
transition (EMT), a key step in the acquisition of malignant behavior,
where epithelial tumor cells gain mesenchymal traits that enable
them to invade and migrate to distant sites.27 We measured in tumors
a panel of EMT inducers (Twist, Snai1, Src), and mesenchymal (Vim)
as well as epithelial (Ocln, Cdh1) markers. The ITPP-induced
changes (upregulation of epithelial markers at the expense of
EMT inducers and mesenchymal markers, Fig. 3C) were fully
consistent with a lasting suppression of the EMT.
In agreement, serum markers of systemic malignancy (osteo-
pontin, CXCL12) and inflammation (HMGB1) fostered through
hypoxia28 were diminished by ITPP in a short and long term
(Fig. 3D). Importantly, ITPP treatment also reduced serum GFP
signals, an indirect measure for the number of circulating, GFP-
tagged tumor cells (Fig. 3E).
Together, these findings indicate that ITPP treatment not only
slows the growth of the primary, but also reduces its malignant
potential in a lasting way.
ITPP Counteracts the Development of Hepatic CRC
Metastases and Displays Additive Effects With
Chemotherapy
To determine whether the ITPP-induced switch to a more
benign tumor phenotype translates into an effective inhibition of
metastatic spread, we determined the frequency and number of
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FIGURE 1. Experimental setup for the study of anticancer
treatments in a syngeneic, orthotopic mouse model of invasive
CRC. The cecal injection of MC-38 cells leads to MRI-detect-
able, intestinal tumors at day 7. Treatment (with ITPP, FOLFOX,
or a combination thereof) was initiated at day 7 and repeated
4 times every other day. Mice were analyzed for short-term
effects at day 17 and for long-term effects at day 60 (6 weeks
after treatment).
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metastases in the liver, the preferred site for CRC spread. To better
appreciate the clinical efficacy, we compared ITPP effects with those
of FOLFOX, the standard treatment for invasive CRC.
In a first step, we assessed the FOLFOX effects on the volume
of the primary so as to confirm its anticancer activity in our model.
Given that ITPP can enhance the effects of conventional chemother-
apy,16,20 we included an animal group exposed to combined ITPP-
FOLFOX treatment. FOLFOX monotherapy reduced primary tumor
volume both in a short and long term with effects akin to those of
ITPP (Fig. 4A). Interestingly, the ITPP-FOLFOX combination dou-
bled the volume reductions achieved through each monotherapy
alone, suggesting ITPP has an additive impact on primary FOLFOX
effects (Fig. 4A). Therefore, FOLFOX is active in our model,
while the combination of ITPP-FOLFOX induces a primary tumor
response superior over monotherapy.
In a second step, we assessed the number of animals with liver
metastasis and the number of colonies per animal at 6 weeks after
treatment. In untreated controls, 60% of animals presented with
liver metastasis. This number was reduced to 50% with FOLFOX,
30% with ITPP, and 25% with ITPP-FOLFOX (Fig. 4B, see also
Supplementary Fig. S1, http://links.lww.com/SLA/B298). Likewise,
the number of metastases per animal was reduced through the
treatment from 18 in untreated controls to about 16, 10, and 7
in the FOLFOX, ITPP, and ITPP-FOLFOX groups, respectively
(Fig. 4C). These observations suggest a stronger antimetastatic effect
for ITPP than for FOLFOX; however, the combination of the 2
treatments led to the most potent suppression of metastatic spread to
the liver.
ITPP Extends Survival of Mice With Metastasizing
CRC and Potentiates the Survival Benefits of
Chemotherapy
The most relevant endpoint with regards to cancer treatment is
survival. To assess whether the effects of ITPP on primary/secondary
CRC and on chemotherapy efficacy impact on survival of tumor-
bearing mice, we repeated the above experiments for a Kaplan–
Meier analysis (Fig. 5).
The mean survival for tumor-bearing mice without treatment
was 75 days from treatment end. Survival was extended to about
111 days (þ48% relative to controls) through both ITPP and FOL-
FOX monotherapies. Intriguingly, the combination of ITPP and
FOLFOX prolonged survival to 170 days (þ127%). Therefore, the
combination of ITPP and FOLFOX has a stronger effect on survival
than on tumor load, suggesting ITPP has some synergistic effect with
FOLFOX on life expectancy in our model. We conclude that ITPP
has a major potential in improving the outcome of invasive CRC
when combined with standard chemotherapy.
DISCUSSION
The most relevant cause of cancer-related death is the meta-
static spread of disease.1–4 A reduction of malignant potential
before the dissemination to distant sites might hence improve
survival. Cytotoxic chemotherapies such as FOLFOX regimen
are currently the treatment of choice for stage III CRC; however,
the resulting survival benefits are small.4,29 The need for novel
approaches in the management of stage III disease remains. Agents
that reduce the risk of developing metastases and that can be
integrated into the current standard of care are particularly desirable.
In this study, we demonstrate that the nontoxic, antihypoxic com-
pound ITPP (i) inhibits the growth and malignant potential of
experimental stage III CRC, (ii) is more efficacious than FOLFOX
in reducing the progression of CRC to the liver, and (iii) markedly
enhances the FOLFOX effects on primary tumor growth, metastatic
development, and survival. Therefore, ITPP meets the key require-
ments to improve the outcomes of standard chemotherapy for
invasive CRC in experimental settings.
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FIGURE 2. ITPP effects on HIF activities in the primary tumors.
A,Hif1a/2agene andHIF1A/2A protein expression in control (C)
and ITPP-exposed (I) tumors immediately (short) or 6 weeks
(long) after treatment. Note the reductions in nuclear HIFs. B,
Tumoral gene expression for the HIF transcriptional target Vegfa
and serumVEGFprotein levels. For all figures: n¼ 6/groupunless
otherwise stated; P < 0.05, P < 0.01, P < 0.001.
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ITPP efficiently inhibited HIF activities in the primary CRC.
The HIFs are key mediators of the hypoxic tumor response, and we
have previously shown in established liver metastases (based on a
similar syngeneic model) that ITPP-mediated tumor oxygenation and
associated HIF inhibition leads to a global suppression of the hypoxic
response, including the angiogenic switch, inhibition of the Warburg
effect (ie, a shift from glucose usage to b-oxidation), improved
immune infiltration, the skewing toward anti-cancerous macrophage
action, and a suppression of malignant potential along with the
promotion of an epithelial, differentiated tumor cell phenotype.16
Indeed, forced activation of the HIFs was sufficient to abort the
beneficial effects of ITPP,16 indicating that the working mode of ITPP
fully depends on the inhibition of HIFs and the hypoxic response.
Here, we focused on the malignant potential, because of its
direct relevance for metastatic spread. ITPP inhibited the hypoxia-
driven EMT,27 consistent with its reported ability to promote in colon
cancer the expression of CDX2, a master promoter of a differentiated
intestinal phenotype.18 Moreover, hypoxia-associated inflammation
is known to induce systemic promoters of malignancy (osteopontin,
CXCL12),28 and ITPP significantly reduced their serum levels,
including those of the key inflammatory mediator HMGB1. ITPP
thus counteracts the epithelial degeneration that confers invasiveness
to cancer cells, and reduces the promotion of their systemic spread, as
evinced by the lesser numbers in circulating tumor cells. Given
the current lack of direct evidence, however, it was important to
demonstrate that ITPP does have an impact on the development of
metastases at distant sites.
As expected from the phenotypic changes observed in the
primary, ITPP was more efficient than FOLFOX in trimming the
metastatic load. On the other hand, the survival benefit was similar
for the 2 monotherapies. Survival strongly correlated with the long-
term reductions in primary volume (R2¼0.996), but also with the
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metastatic load (ie, incidence multiplied by metastatic numbers,
R2¼0.896), suggesting that both the primary and secondary
tumors have contributed to the animals’ death. As such, our model
may not fully reflect human CRC, where metastasis remains the main
cause of death. Furthermore, our findings are based on one model
only. Given that hypoxia is a key driver of malignant conversion,27
it however is plausible that targeting hypoxia through ITPP will
generally reduce metastatic risks.
The strongest effect on metastatic load and survival was
achieved through the ITPP-FOLFOX combination treatment. ITPP
monotherapy is unlikely sufficient to advance the management of
invasive CRC, but 1 reported key effect of ITPP is the normalization
of tumor-associated vasculature.16,20 Tumor-induced vessels often
are dysfunctional and leaky, leading to irregular supply of oxygen,
nutrients, but also medications.30 We have shown that ITPP causes
stable normalization of tumor vasculature16; vessel normalization, in
turn, improves the delivery of cytotoxics to cancer cells, explaining
the synergistic effects of ITPP plus FOLFOX on survival. The lasting
normalization effects point to another key advantage of ITPP, that is,
the provision of a therapeutic window that enables the sequential use
of ITPP followed by standard chemotherapy.16 In this way, potential
drug–drug interactions or cumulative toxicities should be mini-
mized, enabling the use of ITPP without compromising the standard
of care.
The ability of ITPP to normalize vessels further implies that
the compound will improve delivery of any anticancer agent and
hence may be applied for a wide variety of diseases. In support of the
latter, ITPP has been shown to markedly improve the efficacy of
gemcitabine in experimental pancreatic cancer.20 Moreover, ITPP
does not affect cancer cells directly,16 but acts on the tumor envi-
ronment (eg, hemoglobin).15 Unlike cancer cells, the environment
should be genetically stable, implying that the development of
resistance against ITPP is an unlikely event. Genetic instability
however may affect ITPP efficacy; unstable cancer cells are likely
to adapt to unfavorable conditions over time, producing malignant
clones that thrive under hypoxia. It therefore is possible that the
antihypoxic properties of ITPPwill have little effect in very advanced
stages. Only clinical testing will reveal the indications amenable to
ITPP. Importantly, ITPP has not been associated with any toxicity
either in animals (also at doses well above those used here)16 or in
healthy volunteers (http://normoxys.com/clinical-trial-results/). We
thus have initiated a first-in-patient phase Ib/IIa trial to assess the
safety of ITPP and to obtain a first estimate for the ITPP effects on
standard-of-care treatment.31
In summary, our findings indicate a potential for ITPP in
improving the existing management of invasive CRC. ITPP’s most
important feature is its ability to enhance the efficacy of standard
chemotherapy against primary and secondary tumors. Thus, ITPP
can be integrated into current treatment approaches without
compromising standard of care. Moreover, ITPP alone has antime-
tastatic activity besides its effects on the primary. Together with its
low toxicity16 and its beneficial effects on physical capacity,32 the use
of ITPP in the clinic deserves promotion.
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DISCUSSANTS
Peter A. Lodge (Leeds, UK):
There is no doubt that this is an important and well carried out
study and I congratulate the Zurich team for this excellent work.
Thank you for allowing me to see the manuscript before the
presentation and for altering the manuscript title to emphasise that
this was a study of the effects of ITPP, rather than oxygen.
Your data suggest that the inhibition of hypoxia through
increased release of oxygen from hemoglobin is the key mechanism
underlying ITPP action and this inhibits tumor hypoxia, which in turn
leads to HIF (hypoxia inducible factors) inactivation and the sup-
pression of the hypoxic response. First, if this is true, this directly
challenges the use of drugs that act against VEGF such as Bevaci-
zumab. Are you able to comment further on that? Second, a signifi-
cant proportion of patients will not benefit from combination
chemotherapy. Can you speculate how efficacious (or how consis-
tently effective) we should expect ITPP to be? Third, ITPP has been
used in race horses and greyhounds to increase exercise capacity and
I understand trials for heart failure are ongoing. It seems to be a new
‘‘wonder drug’’ – Are you taking it and should we all be?
Response from Perparim Limani
(Zurich, Switzerland):
Thank you Professor Lodge for your appreciation of our paper
and your highly relevant questions. Indeed, our data challenge the
concept of anti-VEGF treatment (eg, Bevacizumab). In our previous
work on experimental stage IV CRC (PMID: 27489288), we directly
compared ITPP plus FOLFOX with anti-VEGF plus FOLFOX and
experimentally documented the marked superiority of the ITPP-
FOLFOX combination in terms of survival benefits. The likely
reason is that ITPP – by increasing oxygenation – inhibits the
complete hypoxic tumor response (a recognized driver of malignan-
cy), while anti-VEGF only counteracts the angiogenic response –
which possibly even worsens hypoxia. The latter might explain why
anti-VEGF therapy is not consistently associated with an improved
overall survival (eg, PMID: 27866194, 27840192, 27081084).
How efficacious ITPP will be in enhancing chemotherapy in
patients remains to be assessed. We are running a clinical trial to
evaluate ITPP in patients with hepato-pancreato-biliary neoplasms
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(ClincialTrials.gov ID: NCT02528526), which will give first data on
the combination of ITPP with standard cytostatics. We believe ITPP
will be efficient in situations, where the tumor still responds to
oxygenation changes. If disease, however, is too progressed (ie, after
years of chronic hypoxia), cancer cells might not care anymore about
oxygen levels and may become less sensitive toward ITPP.
You obviously did good research on the topic. ITPP indeed
seems to be used as a doping agent, largely due to its performance-
enhancing capacities (increased oxygen availability during exercis-
ing). Currently, ITPP is administered via infusion (no oral formu-
lations exist as yet), therefore inappropriate for private use. It has
some potential for a wonder drug, but no data on long-term side
effects in humans are available so far. We thus cannot recommend its
nonmedical intake at the present stage.
Christiane Bruns (Cologne, Germany):
Thank you very much for your presentation. I have 3 ques-
tions: How solid is the animal model with respect to production of
liver metastases over time? How many animals developed liver
metastases after tumor cell injection and how much time was needed
to develop liver metastases in this animal model? The second
question is, when you analyzed RNA and protein levels of all
different factors regarding inflammation, angiogenesis, EMT, and
further on, did you handle tumor heterogeneity? Did you pool all
liver metastasis of all animals with or without treatment to analyse
RNA and the protein levels of the above-mentioned molecular
markers?
Furthermore, ITPP – as you said – decreases the binding
efficacy of hemoglobin in erythrocytes. So, if you think of a clinical
situation, you need to evaluate baseline hemoglobin levels and
erythrocyte counts. I haven’t seen this. Have you analyzed hemoglo-
bin levels and erythrocyte counts in the animals and have you done
this in the starting clinical since this seems to be important for the
efficacy of ITPP?
I haven’t really understood the underlying biological effect of
the drug. It obviously interacts with angiogenesis, inflammation,
EMT, and other biological functions. But, would it be possible to
really use this in the clinic? Could you please comment on those
3 questions?
Response from Perparim Limani
(Zurich, Switzerland):
Thank you Professor Bruns for your important questions.
Regarding the first question, we used an animal model of cecal
injection described first over 40 years ago. In this model, over 60% of
the animals develop liver metastases by day 60 after cancer injection,
with metastases being first detectable on MRI at day 30. It is thus a
fairly robust model of metastatic development.
As for your second question, the study was not set out to
consider tumor heterogeneity. We, however, measured parameters in
tumors with a diameter of at least 1mm to enrich for hypoxic ones
(hypoxia usually develops in tumors larger than 200mm). We ana-
lyzed individual tumors, and we targeted tissue between the periph-
ery and the core to analyze hypoxic regions not hampered through
necrotic changes. ITPP decreases the oxygen binding affinity of
hemoglobin, however has no significant long-term effects on blood
parameters in animals (eg, RBC count, hemoglobin, hematocrit etc.,
see PMID: 21370375). We therefore have not analyzed hematologi-
cal parameters, which, however, are standard parameters assessed for
our patient trial. Thus far, ITPP has not been associated with
unwanted side effects (see, eg, http://normoxys.com/clinical-trial-
results/) and might even have beneficial effects on cardiovascular/
physical performance of patients (PMID: 19204295) – good con-
ditions for its clinical use.
Finally, the primary working mode of ITPP (ie, via increased
oxygen release under low oxygen tension) is the inhibition of tumor
hypoxia, which leads to the inactivation of the HIFs and consequently
the inhibition of the HIF-dependent hypoxic tumor response (that is
angiogenesis, inflammation, EMT, and other biological functions). In
our previous publication (PMID: 27489288), we have shown that all
survival benefits of ITPP are lost if animals are cotreated with a
HIF activator.
Antonio Pinna (Bologna, Italy):
Thank you Dr. Limani for your interesting study. I have a few
brief questions for you. First, you have shown us that overtime the
beneficial effect of ITPP is going to decrease. Could you give us an
answer for that? Second, you have shown us that the metastatic mass
is going to decrease in the model with ITPP and Folfox combined.
Could you tell us how did the animals die? And then finally, you
correctly stated that the experiment was done to replicate treatment in
stage III colorectal cancer. However, I’ve seen you have already
started with the phase-2 trial in humans where they are stage IV. So, I
still think it will probably be interesting to add anti-VEGF in the
animal models study combined with ITPP just considering the use for
stage IV patients.
What about the long-term efficacy of the ITPP? You have
shown us that some molecular beneficial effects of the ITPP can be
lost over time. Have you seen a statistical decrease of all the
biomarkers that you measured?
Response from Perparim Limani
(Zurich, Switzerland):
Thank you Professor Pinna for your questions. Perhaps I did
not present our findings clearly enough, but 1 outstanding feature of
ITPP is that its anticancer effects seem to be long-lasting. The
reduction in malignancy parameters 6 weeks after treatment was
similar to that immediately after treatment – any seeming differences
were not significant. In a previous study, we observed an antitumor
response stable for at least 4 weeks. How long the ITPP effects may
last is unknown, but we assume that once tumor vasculature has been
normalized through ITPP (see our study PMID: 27489288), the
antihypoxic state may be rather stable. However, we cannot expect
the ITPP effects to remain completely stable, since tumors and their
biology are likely to change with time.
Regardless of treatment, mice died either of portal compres-
sion, caval compression, intestinal congestion, or a combination
thereof, indicating that both the growth of primary CRC and second-
ary liver tumors contributed to mortality. As for the stages, here we
used a stage III CRC model, while in our previous study, we
demonstrated efficacy for ITPP in a stage IV model (PMID:
27489288, with established liver metastasis). Our clinical trial is
on stage IV patients, simply because this is the usual patient
population available for first-in-patient studies.
Currently, we would not advise for an ITPP-anti-VEGF
combination. ITPP increases oxygenation and thereby causes HIF
inhibition followed by VEGF downregulation. Anti-VEGF would
additionally reduce VEGF levels likely to the point inhibiting any
angiogenesis. This in turn would enhance hypoxia, the primary target
of ITPP. It hence seems to make little sense to combine these 2
opposing agents. Of note, ITPP-FOLFOX was much more efficient
than anti-VEGF-FOLFOX in our stage IV CRC model.
Rene´ Adam (Villejuif, France):
I really enjoyed your paper. A brief question: The standard
treatment today of metastatic colorectal cancer is, as you know,
doublets or triplets with targeted therapy. So, I would have been very
interested in your animal model to see a group treated with Folfox
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with an antiangiogenic factor like Bevazizumab, because by adding
an antiangiogenic effect, we may stipulate that we will have more
necrosis, more hypoxia and it will be very interesting to know if ITPP
is acting with more activity or not in this setting? What do you think
about that?
Response from Perparim Limani
(Zurich, Switzerland):
Thank you Professor Adam for your interesting question. Our
mouse CRC model is similar to stage III human disease, for which
antiangiogenic agents are not recommended – therefore we did not
include anti-VEGF in this study. However, we compared anti-VEGF-
FOLFOX with ITPP-FOLFOX combinations in our previous study
using a ‘‘stage IV’’-mouse model (PMID: 27489288). There, ITPP-
FOLFOX led to a markedly improved survival relative to anti-VEGF-
FOLFOX treatment. With regards to a combination of ITPP with
anti-VEGF, we would predict lesser activity for ITPP, because its
antihypoxic action would be counteracted by the pro-hypoxic action
of anti-VEGF. ITPP alone reduces VEGF levels, while adding anti-
VEGF may completely block angiogenic activities and thereby
promote hypoxia. But you are right, only experimental testing would
show whether our prediction is correct.
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